Proprietary ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive PTCL and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND cleared for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Phase l or ll
Hematology, Immuno-Oncology, Oncology
100MM - 500MM
Antibodies, Platform Technology
Im Neuenheimer Feld 582
Heidelberg, Baden-Wurttemberg 69120
Disease Target CD30 Immune Cell Target CD16A
Hodgkin lymphoma + PD-1
Hodgkin lymphoma + adoptive NK cells
Disease Target EGFRwt Immune Cell Target CD16A
Top 10 Holders of Affimed N.V.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by